Kikuchi Takayuki, Ishii Akira, Nakahara Ichiro, Miyamoto Susumu, Sakai Nobuyuki
Department of Neurosurgery, Kyoto University Graduate School of Medicine.
Neurol Med Chir (Tokyo). 2014;54(1):40-5. doi: 10.2176/nmc.st2013-0194. Epub 2013 Nov 21.
Although utilization of endovascular treatment of extracranial steno-occlusive lesions except for internal carotid artery stenosis continues to increase, there is no consensus regarding the natural course and standard treatment of these lesions. The aim of this study was to characterize the utility of endovascular treatment for extracranial steno-occlusive lesions except for internal carotid artery stenosis. A total of 1249 procedures for extracranial steno-occlusive lesions were identified from the Japanese Registry of Neuroendovascular Therapy (JR-NET) and JR-NET2. Excluding the cases of carotid lesions (290 cases), endovascular procedures were performed for 471 (37.7%) subclavian artery stenoses, 404 (32.3%) extracranial vertebral artery stenoses, and 38 (3.0%) innominate artery stenoses with a technical success rate of 97.2%. A stent was placed for 783 lesions and percutaneous transluminal angioplasty was performed for 183 lesions. Forty complications were reported in this cohort. Among these, ischemic complications were the most frequent (12 cases). Comparison between JR-NET1 and JR-NET2 demonstrated a marked increase in the number of procedures, a change in the utilization of antiplatelet therapy, and an increased rate of favorable outcome. We conclude that the endovascular treatment for extracranial steno-occlusive lesions is relatively safe. Continuous efforts should be made to reduce the complication rate, and further trials are needed to validate the beneficial effect of this procedure.
尽管除颈内动脉狭窄外的颅外狭窄闭塞性病变的血管内治疗应用持续增加,但对于这些病变的自然病程和标准治疗尚无共识。本研究的目的是明确除颈内动脉狭窄外的颅外狭窄闭塞性病变血管内治疗的效用。从日本神经血管内治疗注册系统(JR-NET)和JR-NET2中识别出总共1249例颅外狭窄闭塞性病变的治疗程序。排除颈动脉病变病例(290例)后,对471例(37.7%)锁骨下动脉狭窄、404例(32.3%)颅外椎动脉狭窄和38例(3.0%)无名动脉狭窄进行了血管内治疗,技术成功率为97.2%。783处病变置入了支架,183处病变进行了经皮腔内血管成形术。该队列报告了40例并发症。其中,缺血性并发症最为常见(12例)。JR-NET1和JR-NET2之间的比较显示治疗程序数量显著增加、抗血小板治疗的应用发生变化以及良好结局率提高。我们得出结论,颅外狭窄闭塞性病变的血管内治疗相对安全。应持续努力降低并发症发生率,还需要进一步试验来验证该治疗方法的有益效果。